首页> 外文OA文献 >The Role of Serotonin in the Development of Psychiatric Disorders: Studies on Drug Dependence and Anxiety-like Behaviour Following the Genetic Reduction of the Serotonin Transporter
【2h】

The Role of Serotonin in the Development of Psychiatric Disorders: Studies on Drug Dependence and Anxiety-like Behaviour Following the Genetic Reduction of the Serotonin Transporter

机译:5-羟色胺在精神疾病发展中的作用:5-羟色胺转运蛋白遗传还原后药物依赖性和焦虑样行为的研究

摘要

Rationale: Given the high prevalence and large burden of psychiatric disorders it is imperative to determine the underling etiology in order for better understanding and treatment. The neurotransmitter serotonin (5-HT) has been associated with mental disorders in humans both pharmacologically and genetically. Individuals with the short-allele of a prominent polymorphism within the 5-HT transporter (SERT) show increased incidence of mood disorders and drug dependence. However, whether or not dysregulation in the 5-HT system causes, or is just associated with, psychiatric disorders is impossible to determine from human studies alone. Consequently, it is imperative to employ an animal model of down-regulated SERT function. To better understand the role of 5-HT in drug dependence, the rat’s behavioural response to the psychostimulant (±) 3, 4-methylenedioxymethamphetamine (MDMA), a preferentially serotonergically mediated drug, was assessed. Finally, the ability to rescue the anxiety-like phenotype in the SERT-/- rat by altering extracellular 5-HT during early development was also evaluated.Objective: The primary objective of the current thesis was to determine whether dysregulation of 5-HT is directly linked to the occurrence of psychiatric disorders, particularly drug dependence and anxiety.Methods: A model of down-regulated SERT function, the SERT knock-out (SERT-/-) rat, was used for all experiments in order to determine a causal relationship between 5-HT dysregulation and psychiatric disorders. In Chapter 2, the response of the SERT-/- rats to various tasks usually disrupted by MDMA was assessed. In Chapter 3, the sensitivity of the SERT-/- rats to the reinforcing effects of MDMA was determined using the self-administration paradigm. Finally, in Chapter 4, whether the anxiety-like behaviour of the SERT-/- rat could be rescued through normalising excessive extracellular 5-HT neonatally was assessed. An attempt was also made to determine a mechanism by which 5-HT dysregulation could alter behaviour. To this end, gene expression previously found to be up- or down-regulated in the SERT-/- rat was assessed in the neonatally treated rats.Results: The results of Chapter 2 indicated the SERT is necessary for MDMA’s disruption of startle habituation but not its psychomotor effects. Moreover, for those rats that could discriminate low dose MDMA from saline, genetic removal of the SERT resulted in the inability to discriminate MDMA from amphetamine, implying that, in these rats, MDMA was now subjectively indistinguishable from amphetamine. Indeed, this alteration also resulted in enhanced sensitivity to the reinforcing properties of MDMA, giving MDMA the qualities of a traditional psychostimulant in SERT-/- rats (Chapter 3). Finally, lowering the excessive 5-HT during neonatal development in SERT-/- rats led to a rescue of mild, but not high, anxiety-like behaviour in males. However, mRNA levels of long 3’NTR BDNF and 5-HT1a, genes associated with neurodevelopment, remained unchanged across genotypes and treatment groups (Chapter 4).Conclusions: Genetic removal of the 5-HT transporter results in an altered behavioural response to MDMA, in particular an increased sensitivity to its reinforcing properties. However, while the genetic removal of the SERT results in enhanced extracellular 5-HT, the pathological phenotypes present in this rat are likely due to this increase occurring in early development, not its continued presence in adulthood. Overall, these findings contribute to the growing body of literature indicating that enhanced brain 5-HT during early development can lead to pathological behaviour in adulthood.
机译:理由:鉴于精神疾病的高患病率和高负担,必须确定基本病因,以便更好地理解和治疗。神经递质5-羟色胺(5-HT)在药理和遗传学上都与人类精神疾病有关。在5-HT转运蛋白(SERT)中具有突出多态性的短等位基因的个体显示出情绪障碍和药物依赖性的发生率增加。但是,仅凭人体研究无法确定5-HT系统失调是引起精神疾病还是与精神疾病有关。因此,必须采用下调SERT功能的动物模型。为了更好地了解5-HT在药物依赖性中的作用,评估了大鼠对精神兴奋药(±)3、4-亚甲二氧基甲基苯丙胺(MDMA)(一种优先通过血清素介导的药物)的行为反应。最后,还评估了通过在早期发育过程中改变细胞外5-HT来挽救SERT-/-大鼠焦虑样表型的能力。目的:本论文的主要目的是确定5-HT失调是否为方法:与SERT功能下调的模型SERT基因敲除(SERT-/-)大鼠用于所有实验,以确定是否有因果关系。 5-HT失调与精神疾病之间的关系。在第二章中,评估了SERT-/-大鼠对通常被MDMA破坏的各种任务的反应。在第3章中,使用自我管理范式确定了SERT-/-大鼠对MDMA增强作用的敏感性。最后,在第4章中,评估了是否可以通过使新生儿过多的细胞外5-HT正常化来挽救SERT-/-大鼠的焦虑样行为。还尝试确定5-HT失调可改变行为的机制。为此,在新生治疗的大鼠中评估了先前在SERT-/-大鼠中被发现上调或下调的基因表达。结果:第2章的结果表明,SERT对于MDMA破坏惊吓的习惯是必需的,但而不是它的心理运动效果。而且,对于那些可以从盐水中区分出低剂量MDMA的大鼠来说,SERT的遗传去除导致无法将MDMA与苯丙胺区分开,这意味着在这些大鼠中,MDMA现在与苯丙胺在主观上无法区分。确实,这种改变还导致对MDMA增强特性的敏感性增强,使MDMA具有SERT-/-大鼠中传统精神刺激药的特性(第3章)。最后,降低SERT-/-大鼠新生儿发育过程中过量的5-HT可使男性缓解轻度但不高的焦虑样行为。然而,在基因型和治疗组中,与神经发育相关的长3'NTR BDNF和5-HT1a的mRNA水平保持不变(第4章)。结论:5-HT转运蛋白的遗传去除导致对MDMA的行为反应发生改变。 ,特别是对其增强性能的敏感性提高。然而,尽管SERT的遗传去除导致细胞外5-HT增强,但存在于该大鼠中的病理表型可能是由于早期发育中出现这种增加,而不是成年后继续存在。总体而言,这些发现促进了越来越多的文献研究,表明在早期发育过程中增强脑5-HT可以导致成年期的病理行为。

著录项

  • 作者

    Oakly Alana;

  • 作者单位
  • 年度 2015
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_NZ
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号